Work for Pieris Pharmaceuticals, Inc. ?

Claim Your Profile

Pieris Pharmaceuticals, Inc.  Logo Image

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.  Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

About Pieris Pharmaceuticals, Inc.

51-200 Employees
Based in Boston, Massachusetts

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases, immuno-oncology multi-specifics tailored for the tumor microenvironment, and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.

Ticker:
PIRS
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol